Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

N Engl J Med. 2017 Jan 12;376(2):191-192. doi: 10.1056/NEJMc1614298.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Duodenal Neoplasms / drug therapy*
  • Humans
  • Kidney Transplantation*
  • Liver Neoplasms / secondary
  • Male
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Programmed Cell Death 1 Receptor
  • Nivolumab